259 related articles for article (PubMed ID: 22435504)
61. Mesalamine with MMX technology for the treatment of ulcerative colitis.
Schreiber S; Kamm MA; Lichtenstein GR
Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
[TBL] [Abstract][Full Text] [Related]
62. [Once daily mesalazine for long-term remission. Ulcerative colitis: maintenance therapy becomes easier].
MMW Fortschr Med; 2008 Mar; 150(11):44-5. PubMed ID: 18447278
[No Abstract] [Full Text] [Related]
63. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
Miner PB; Wedel MK; Xia S; Baker BF
Aliment Pharmacol Ther; 2006 May; 23(10):1403-13. PubMed ID: 16669955
[TBL] [Abstract][Full Text] [Related]
64. [Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis].
Lakatos PL; Lakatos L
Orv Hetil; 2009 Mar; 150(9):397-404. PubMed ID: 19228568
[TBL] [Abstract][Full Text] [Related]
65. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
Andus T; Kocjan A; Müser M; Baranovsky A; Mikhailova TL; Zvyagintseva TD; Dorofeyev AE; Lozynskyy YS; Cascorbi I; Stolte M; Vieth M; Dilger K; Mohrbacher R; Greinwald R;
Inflamm Bowel Dis; 2010 Nov; 16(11):1947-56. PubMed ID: 20310020
[TBL] [Abstract][Full Text] [Related]
66. Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study.
Hiwatashi N; Suzuki Y; Mitsuyama K; Munakata A; Hibi T
J Gastroenterol; 2011 Jan; 46(1):46-56. PubMed ID: 20878425
[TBL] [Abstract][Full Text] [Related]
67. Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.
Lichtenstein GR; Barrett AC; Bortey E; Paterson C; Forbes WP
Inflamm Bowel Dis; 2014 Aug; 20(8):1399-406. PubMed ID: 24874460
[TBL] [Abstract][Full Text] [Related]
68. Decision tree construction and cost-effectiveness analysis of treatment of ulcerative colitis with pentasa® mesalazine 2 g sachet.
Nishikawa AM; Paladini L; Delfini R; Kotze PG; Clark O
Arq Gastroenterol; 2013; 50(4):297-303. PubMed ID: 24474233
[TBL] [Abstract][Full Text] [Related]
69. Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Zhao X; Li N; Ren Y; Ma T; Wang C; Wang J; You S
PLoS One; 2016; 11(8):e0160500. PubMed ID: 27501314
[TBL] [Abstract][Full Text] [Related]
70. Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.
Cuffari C; Pierce D; Korczowski B; Fyderek K; Van Heusen H; Hossack S; Wan H; Edwards AY; Martin P
Drug Des Devel Ther; 2016; 10():593-607. PubMed ID: 26893546
[TBL] [Abstract][Full Text] [Related]
71. Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?
Lakatos PL; Lakatos L
Pharmacol Res; 2008; 58(3-4):190-5. PubMed ID: 18801439
[TBL] [Abstract][Full Text] [Related]
72. A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study.
Gifford AE; Berg AH; Lahiff C; Cheifetz AS; Horowitz G; Moss AC
Am J Gastroenterol; 2013 Feb; 108(2):249-55. PubMed ID: 23295279
[TBL] [Abstract][Full Text] [Related]
73. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.
Yarlas A; D'Haens G; Willian MK; Teynor M
Inflamm Bowel Dis; 2018 Jan; 24(2):450-463. PubMed ID: 29361097
[TBL] [Abstract][Full Text] [Related]
74. Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Chen X; Hou J; Yuan Y; Huang C; Liu T; Mo C; Li H; Chen B; Xu Q; Hou Z; He W; Liu F
BioDrugs; 2016 Jun; 30(3):207-17. PubMed ID: 27120055
[TBL] [Abstract][Full Text] [Related]
75. 2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial.
Suzuki Y; Iida M; Ito H; Nishino H; Ohmori T; Arai T; Yokoyama T; Okubo T; Hibi T
Inflamm Bowel Dis; 2017 May; 23(5):822-832. PubMed ID: 28368909
[TBL] [Abstract][Full Text] [Related]
76. MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.
Hu MY; Peppercorn MA
Expert Opin Pharmacother; 2008 Apr; 9(6):1049-58. PubMed ID: 18377346
[TBL] [Abstract][Full Text] [Related]
77. Preparation and evaluation of mesalamine collagen in situ rectal gel: a novel therapeutic approach for treating ulcerative colitis.
Ramadass SK; Perumal S; Jabaris SL; Madhan B
Eur J Pharm Sci; 2013 Jan; 48(1-2):104-10. PubMed ID: 23137838
[TBL] [Abstract][Full Text] [Related]
78. [Optimization of cell therapy in patients with inflammatory bowel diseases].
Lazebnik LB; Knyazev OV; Parfenov AI; Ruchkina IN; Shcherbakov PL; Khomeriki SG; Konoplyannikov AG
Ter Arkh; 2012; 84(8):10-7. PubMed ID: 22994082
[TBL] [Abstract][Full Text] [Related]
79. The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands.
Connolly MP; Boersma C; Oldenburg B
Neth J Med; 2012 Aug; 70(6):272-7. PubMed ID: 22859419
[TBL] [Abstract][Full Text] [Related]
80. Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose.
Khan N; Abbas AM; Koleva YN; Bazzano LA
Inflamm Bowel Dis; 2013 May; 19(6):1123-9. PubMed ID: 23514878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
